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Patients who receive radiotherapy to the neck are at increased risk
of developing thyroid dysfunction – usually biochemical hypo-
thyroidism, but occasionally clinical hypothyroidism or thyro-
toxicosis (Green et al, 1980; Kaplan et al, 1983; Constantine et al,
1984; Hancock et al, 1991; Peerboom et al, 1992). They are also
more likely to develop both benign and malignant nodules of the
thyroid gland (Stewart et al, 1989; Soberman et al, 1991). In 1991,
we started a prospective study of the thyroid gland in patients
whose treatment for Hodgkin’s disease in childhood had included
radiotherapy to the neck. The aim of the study was to gather infor-
mation on the natural history of thyroid nodular disease following
neck radiotherapy for childhood Hodgkin’s disease and, using this
information, to devise a protocol for the appropriate follow-up of
these patients.
METHODS
The thyroid gland of 47 patients who had received radiotherapy to
the neck for Hodgkin’s disease during childhood was prospec-
tively investigated by: (i) clinical examination, (ii) thyroid func-
tion tests, and (iii) thyroid ultrasound scan. These investigations
were repeated at approximately yearly intervals. Thyroid function
tests undertaken prior to entry into the study were also reviewed.
For patients with a raised thyroid-stimulating hormone (TSH)
level, the time interval between radiotherapy and the first elevated
TSH level, and also the length of time that the TSH level remained
raised, were calculated. Only patients whose first TSH level was
recorded within 2 years of radiotherapy and who had levels
measured regularly at no more than 2-yearly intervals were
included in this calculation. When the TSH was elevated and
remained elevated for 12 months, the patient was started on
thyroxine.
All the ultrasound scans were carried out by one of three radiol-
ogists (JCH, RHR, JAWW). Focal abnormalities were identified
and, on follow-up scans, any change to previously noted abnor-
malities or new focal lesions was recorded. Patients with a focal
abnormality of 0.5 cm or greater were further investigated by
radionuclide imaging and/or fine-needle aspiration biopsy (FNA).
A small number of patients underwent thyroid surgery when the
nature of the abnormality noted on the ultrasound scan remained in
doubt.
Analysis
Statistical analysis was done using the Minitab software. Patients
with, and without, a focal abnormality on the first thyroid ultra-
sound scan were compared looking at: gender, age at radiotherapy,
length of follow-up since radiotherapy, presence of a raised TSH
level and the length of time the TSH level remained elevated.
The c2 test was used for comparison of proportions and the
Mann–Whitney test for continuous variables.
RESULTS
A total of 47 patients with Hodgkin’s disease diagnosed between
1973 and 1989 were included in this study. Their characteristics
are shown in Table 1. All patients had received radiotherapy to the
neck, 14 to the neck alone and 33 to the neck and mediastinum.
The median dose to the neck was 35 Gy (range 2250–4000 cGy).
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At the time of their initial scan, six patients had abnormal clinical
findings. Five patients had palpable abnormalities of the thyroid
gland or neck and were all more than 10 years from radiotherapy
(Table 2). The remaining patient had signs of thyrotoxicosis 4
years from radiotherapy.
Thyroid function tests
Thirty patients had abnormal thyroid function tests, either at the
time of the first scan or documented at some time previously, with
all but one patient, who had thyrotoxicosis, having a raised TSH
level. The median time interval from radiotherapy to the first
elevated TSH level was 27 months, range 2–94 months. Only two
patients had a low level of thyroxine. Thirteen patients were on
thyroxine at the time of their first scan and four were subsequently
started on thyroxine because of a persistently elevated TSH level.
In 12 patients, the TSH level had returned to normal spontaneously
prior to the start of the study, over a period of time ranging from 9
to 100 months, median 33 months.
Ultrasound scans
All patients had an abnormal thyroid ultrasound scan. Forty-five
patients (95%) had diffuse atrophy whilst two had a goitre. Twenty
patients (42%) had a focal abnormality. The majority (15) of these
patients had multiple focal abnormalities, but five patients had a
single focal abnormality. The size of the focal lesion was also vari-
able and in five patients the lesion was > 1 cm. More detail of the
sonographic abnormalities which can occur after radiotherapy to
the neck for childhood Hodgkin’s disease is given in the paper by
Healy et al (1996).
Characteristics of patients with a focal abnormality compared to
those without a focal abnormality are shown in Table 3. Using the
c2 test a significant association was demonstrated between focal
abnormality and younger age at radiotherapy (P < 0.02) and longer
follow-up (P < 0.01). There was also an association between focal
abnormality and the length of time that the TSH level remained
elevated (P < 0.09). However, no relationship was demonstrated
between the presence of a focal abnormality and gender, or a
raised TSH level.
Table 4 shows the frequency of abnormal thyroid function tests
and thyroid nodules on ultrasound related to lymphangiography
and dose of radiotherapy. These differences were not significant.
Ten patients had an ultrasound scan within 5 years of radio-
therapy. Only two patients developed a focal abnormality within
this time period. Both of these patients had evidence of auto-
immune thyroid dysfunction with thyroid auto antibodies, one
patient having thyrotoxicosis and the other hypothyroidism.
Relationship of thyroxine therapy to the development
of thyroid nodular disease
In order to obtain information on the natural history of thyroid
nodular disease after neck radiotherapy for childhood Hodgkin’s
disease, patients were divided into two groups: those not on
thyroxine and those taking thyroxine at the point of entry into the
study. Four patients were started on thyroxine during the course of
the study and were therefore censored from the first group at that
point.
Group 1 – patients not on thyroxine
Thirty-four patients were not on thyroxine at the time of the initial
scan. Median follow-up from radiotherapy to first thyroid ultra-
sound scan was 13 years 5 months (range 6–21 years). Five
patients are excluded from the following data. Three of these
patients had surgery because of the findings on the initial scan, and
two patients were started on thyroxine because of a persistently
elevated TSH level.
Twenty-nine patients, nine of whom had a focal abnormality on
the initial scan, had between two and five further scans over a
period of time ranging from 3 to 6 years, median 5 years 3 months.
In four patients the multiple focal abnormalities noted on the
initial scan remained unchanged throughout the study. Two of the
patients had lesions less than 0.5 cm, one of whom had never had a
raised TSH level, whilst the other had been treated for thyrotoxi-
cosis. The other two patients had lesions greater than 1 cm in size.
Both had previously had elevated TSH levels which had returned
to normal spontaneously (after 78 months in one patient) prior to
the commencement of the study. TSH levels subsequently
remained normal.
Five patients, whose initial thyroid ultrasound scan was
abnormal, had an increase in size or number of the focal abnormal-
ities. Two of these patients are known to have had elevated TSH
levels, whilst the other three had periods between 3 and 5 years
when no levels were measured but all recorded levels were normal.
Six patients with no focal lesion on the first scan did not develop
any focal abnormality during the course of the study. Five of these
patients had never had a raised TSH level recorded. The sixth
patient had had one elevated TSH level recorded but no more
levels were measured until 7 years later when the TSH was
normal.
Fourteen patients, whose initial scan was normal, developed
focal abnormalities during the course of the study at a median of
11 years 10 months (range 6–18 years) from radiotherapy. The
focal abnormality varied in size from > 1 cm (two patients), 0.6–
1 cm (two patients) to 0.5 cm or less (ten patients). Three patients
developed solitary lesions, the remainder developed between two
and five nodules. Eight of these 14 patients had a raised TSH level,
four during the study period and four at some time previously.
Another patient had an abnormal thyrotrophin-releasing hormone
(TRH) test one year prior to and at the commencement of the
study. Only two of the remaining five patients are known never to
have had a period of over stimulation of the thyroid gland by TSH.
Doubt remains about the other three patients because, although all
the recorded TSH levels are within the normal range, there were
long periods of time between some of the measurements.
Apart from one cystic lesion, no focal lesion present on the
initial scan disappeared during the course of the study. In this
patient other focal abnormalities were also present in the thyroid
gland and these persisted.
The percentage of patients with a focal lesion at 10 years and 15
years from radiotherapy was calculated. To do this several assump-
tions were made. During the course of the study although we
demonstrated an increase in the number of focal lesions, in no
patient did the number of focal lesions decrease, therefore any
patient who had a focal lesion but had not reached 10 years follow-
up from radiotherapy was included in the calculations for both time
periods. Any patient whose initial scan showed a focal lesion but
whose scan was done between 10 and 15 years from radiotherapy
was only included in the calculation of the percentage with focal
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lesions at 15 years. If the inital scan was more than 10 years from
radiotherapy, but did not show a focal lesion, this patient was
included in the denominator for this calculation. The estimated
percentage of patients not on thyroxine developing a focal lesion by
10 years from radiotherapy was 39% and by 15 years was 71%.
Group 2 – patients on thyroxine
Thirteen patients were on thyroxine at the start of the study,
median length of follow-up from radiotherapy to the first ultra-
sound scan for this group of patients was 10 years 3 months (range
4–16 years). One patient subsequently relapsed and died. The
remaining 12 patients, eight of whom had a focal abnormality on
the initial scan had between four and six scans over a period of
time, ranging from 4 to 6 years. It is difficult to get a clear picture
of the behaviour of thyroid nodules after suppression of TSH by
thyroxine, as the thyroid glands of most of these patients had been
subjected to long periods of over-stimulation by TSH (median 41
months, range 4–84 months) before thyroxine was commenced.
Also, in the majority of patients, even after starting thyroxine the
TSH level was not fully suppressed. However, in one patient who
was fully suppressed (TSH level < 1 mu l–1), two focal lesions
< 0.5 cm present on the initial scan were no longer apparent on a
repeat scan 1 year later and did not recur during 4 years of subse-
quent follow-up. A patient who had surgery for a solitary 1 cm
‘cold’ nodule present on the initial scan who had previously had a
raised TSH level for 88 months did not develop any new nodules
in the remaining thyroid lobe over a period of 4 years during which
time the TSH level was fully suppressed. Two other patients
showed a decrease in the size and number of focal abnormalities
during the course of the study. In the remaining four patients who
had focal abnormalities on the initial scan, there was an increase in
either the size or the number of nodules during the course of the
study. None of these patients were adequately suppressed.
Four patients who did not have a focal abnormality on the initial
scan developed focal lesions. In one patient this was a transient
solitary < 0.5 cm nodule which appeared when thyroxine was
discontinued for 6 months, but disappeared when thyroxine was
restarted. Two patients developed multiple nodules of 0.6–1 cm in
size. Neither of these patients were adequately suppressed, one
because of non-compliance and the other because the dose of
thyroxine was initially too low. The fourth patient developed a soli-
tary 0.5 cm nodule 12 years after commencing thyroxine. He had
only been adequately suppressed for the previous 5 years because
of non-compliance. This patient also had thyroid autoantibodies.
Radionuclide scans
Twenty-six patients out of the total of 47 were further investigated
with radionuclide imaging (RNI) because of lesions of 0.5 cm or
greater in size on the ultrasound scan. Fourteen were reported as
showing no focal defect, five a goitre, one a functioning ‘hot’
nodule, and six a ‘cold’ nodule. RNI was not as sensitive as ultra-
sound in identifying thyroid nodules. The smallest nodule identi-
fied on RNI measured 1.3 cm compared to 0.2 cm on ultrasound
scan. No new nodules were detected by RNI.
Fine-needle aspiration
In 11 patients, FNA biopsy was performed under local anaesthetic
and ultrasound guidance, because of continuing concern about the
exact nature of the lesion. All of these patients had multiple focal
abnormalities with at least one lesion 1 cm or greater in size. A
biopsy was performed because of an increase in size or an increase
in the solid component of the focal lesion on serial scanning, and
in one patient because of a grossly abnormal thyroid gland. In five
patients, this procedure was non-contributory as only blood was
obtained in the aspirate. In the other six patients, the aspirate
contained small groups of follicular cells but no definite evidence
of malignancy.
Surgery
Ten patients underwent thyroid surgery, three of whom were
subsequently found to have a thyroid carcinoma. One of these
patients was found to have an isolated ‘cold’ nodule 13 years after
radiotherapy to the neck at the age of 11 years. She had received
25 Gy in 15 fractions over 19 days. All recorded TSH levels were
normal, so she was not on thyroxine prior to surgery. A needle
biopsy was not performed. Histology of the thyroid gland showed
Table 1 Patient characteristics
Total number of patients 47 (31 Male + 16 Female)
Stage at diagnosis
Stage 1 15 patients
Stage 2 18 patients
Stage 3 12 patients
Stage 4 2 patients
No of patients with B symptoms 15
Median age at radiotherapy 12 years 4 months
(range 4 years 7 months to 16 years 7 months)
Median interval from radiotherapy to first scan 10 years 4 months
(range 9 months to 17 years 9 months)
Median length of follow up 14 years 5 months
(range 6 years 2 months to 22 years 11 months)
Median dose of radiotherapy to neck 35 Gy
(range 22.5–40 Gy)
No. of patients who had chemotherapy 36
No. of patients who had a lymphangiogram 27Post-radiation thyroid disease in childhood Hodgkin’s 811
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the presence of a follicular variant of a papillary thyroid carci-
noma. The adjacent thyroid parenchyma showed peripheral vacuo-
lation of colloid as seen in TSH stimulation. The other two patients
had surgery because of a grossly abnormal thyroid gland with
multiple nodules, even though the FNA showed no evidence of
malignancy. One was 20 years from radiotherapy to the neck given
when he was 12 years old. He received 35 Gy in 20 fractions over
27 days. He had had a raised TSH for 18 months, 3 years post-
radiotherapy, but the TSH level returned to normal spontaneously
and so he had not been started on thyroxine. Metastatic papillary
carcinoma was found in one of three cervical nodes removed at
surgery. Two hypoechoic nodules, thought to be lymph nodes,
behind the lower pole of the left lobe of the thyroid had been noted
on ultrasound scan. No focus of carcinoma was found on multiple
sectioning of the thyroid gland. The other patient was also 20 years
from radiotherapy given when he was 10 years old. He received
standard mantle field radiotherapy to a dose of 3000 cGy. All
recorded TSH levels were normal, although there was a 5-year
period, 12 months post-radiotherapy, when no TSH measurements
were done. Histological examination showed thyroid follicles of
varying size, with, in one area, a collection of poorly formed folli-
cles with crowded nuclei, compatible with a microscopic papillary
carcinoma of the thyroid. In addition to the patient mentioned
above, two other patients with ‘cold’ nodules had surgery without
prior biopsy.
Five other patients had surgery, all of whom had previously had
a FNA biopsy. Four patients had an unsuccessful biopsy, and the
fifth had surgery because of concern remaining about a grossly
abnormal gland, even though the biopsy showed no evidence of
malignancy.
In addition to the three patients with a carcinoma of the thyroid
gland, three other patients had a total thyroidectomy, one had a
subtotal thyroidectomy and the remaining three patients had a partial
thyroidectomy. Two of these latter three patients had a solitary lesion.
No further thyroid nodules have developed since surgery over 1 and
4 years follow-up. Both patients are on thyroxine and are fully
suppressed. The third patient had nodules in the remaining thyroid
lobe. These have remained unchanged over a period of 3 years. This
patient is also on a suppressive dose of thyroxine. Histological exam-
ination of all the thyroid glands resected has shown typical radiation
induced changes (Doniach et al, 1987; Carr and Livolsi, 1989).
DISCUSSION
This study confirms the diversity of thyroid disease which may
affect patients whose treatment for Hodgkin’s disease in childhood
included radiotherapy to the neck (Green et al, 1980; Kaplan et al,
1983; Constantine et al, 1984; Stewart et al, 1989; Hancock et al,
1991; Soberman et al, 1991; Peerboom et al, 1992). It also empha-
sizes the need for continuing follow-up of this group of patients.
Although the median time from radiotherapy to the first elevated
TSH level was 26 months some patients may not develop sub-
clinical hypothyroidism until many years later. In this study the
longest documented time interval from radiotherapy to an elevated
TSH level was 7 years 10 months but other studies have noted an
even longer time interval, of up to 18 years (Hancock et al, 1991).
Fifty-seven per cent of patients developed subclinical hypo-
thyroidism and an additional two patients (4%) also had low serum
thyroxine levels These results are comparable to those reported by
Peerboom et al (1992) but others have noted a considerable varia-
tion in the frequency of subclinical hypothyroidism (36–63%)
(Green et al, 1980; Constantine et al, 1984).
In 12 of our patients, elevated TSH levels returned to normal
spontaneously after a median of 33 months. This has also been
noted in some other studies (Constantine et al, 1984; Hancock et
al, 1991) and suggests that there may be a case for discontinuing
thyroxine therapy, given to patients with a raised TSH level, after a
period of time, and performing a TRH test to ascertain whether
thyroxine is still necessary. It is difficult to know how long after
the start of thyroxine treatment this stimulation test should be
carried out. We performed TRH tests in two patients 10 years after
radiotherapy who had been on thyroxine for 5 years. In one
patient, the TSH level had been elevated for 14 months and, in the
other patient, for 63 months prior to the commencement of
thyroxine treatment. In both patients the TRH test was grossly
abnormal and thyroxine therapy was restarted.
This study confirms the insensitivity of thyroid palpation in
Table 2 Abnormal clinical findings.
Palpable thyroid nodule 2
Diffuse goitre 2
Lymph node anterior triangle 1
Signs of thyrotoxicosis 1
Table 3 Comparison of patients with and without focal abnormalities on initial thyroid ultrasound scan
Focal abnormality No focal abnormality
Total no. of patients 20 27
Male:female 11:9 20:7
Median age at radiotherapy 11 years 2 months 13 years 8 months
Range 4 years 7 months to 15 years 9 months 5 years 3 months to 16 years 7 months
Median time since radiotherapy 12 years 1 month 8 years 10 months
Range 3 years 11 months to 17 years 4 months 8 months to 14 years 9 months
No. of patients with raised TSH 14 (70%) 14 (51%)
Median time from radiotherapy to first 30 months 19 months
elevated TSH level
Range 2 months to 51 months 3 months to 94 months
Length of time TSH raised 3 years 10 months 2 years 2 months
Range 4 months to 11 years 7 months to 5 years 2 months
No. of patients on T4 8 (40%) 5 (19%)812 EA Shafford et al
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detecting thyroid nodules (Soberman et al, 1991; Crom et al,
1997). Although thyroid ultrasound scans have been performed
prospectively many of our patients had been off treatment for more
than 10 years before the first scan was done so it is not possible to
say when the abnormality first appeared. However, from the data
collected in ten patients who had scans less than 5 years from
radiotherapy it seems that focal abnormalities are unlikely to
appear in this time period in the presence of normal thyroid func-
tion tests. The number of patients not on thyroxine who developed
a focal lesion increased with increasing time from radiotherapy,
39% at 10 years and 71% at 15 years. Kaplan et al (1983) also
noted increasing frequency of palpable thyroid abnormalities with
increasing length of follow-up.
Prolonged over-stimulation of the thyroid gland by TSH seems
to be an important factor in the development of focal abnormali-
ties. Fourteen of 29 patients not on thyroxine developed a focal
lesion, having previously had a normal scan, and an additional five
patients had an increase in the size or number of focal lesions. Ten
of these 19 patients had had a raised TSH level and one had an
abnormal TRH test on two occasions. Only two of these patients
are known to have always had a normal TSH level. In the
remaining six patients, although all the TSH levels recorded were
normal, there were long periods of time between some of these
measurements.
The precise role of thyroxine in preventing these abnormalities
is difficult to determine from this study as many patients experi-
enced prolonged periods of over stimulation before being started
on thyroxine and few patients have been adequately suppressed.
However, resolution of focal lesions was seen only in the patients
on thyroxine. Fogelfeld et al (1989), in a study of 511 patients who
had surgery for benign thyroid nodules arising after radiotherapy
to the neck for benign disease in childhood, demonstrated that
treatment with thyroxine reduced the number of recurrences of
benign nodules but did not affect the rate of thyroid cancer.
Whilst there would seem to be general agreement about treating
patients with a raised TSH level after radiotherapy to the neck,
with thyroxine to prevent over-stimulation of the thyroid gland, the
optimum treatment of patients who have a TSH level in the normal
range but an abnormal thyroid ultrasound scan is less clear. Our
current practice is to treat such patients with thyroxine to suppress
the production of TSH. It is too early to say whether this policy has
led to a reduction in the number of patients with abnormal thyroid
ultrasound scans but during the course of this study patients not on
thyroxine continued to develop new focal lesions and only in the
patients on thyroxine was any decrease in the number of focal
lesions demonstrated.
In our study there was no difference in the frequency of thyroid
dysfunction dependent on whether or not the patient had had a
lymphangiogram at diagnosis. This is in agreement with the find-
ings of Fleming et al (1985). However, some studies have shown
an increase in thyroid dysfunction associated with lymphangiog-
raphy (Kaplan et al, 1983), whereas others have shown a protec-
tive effect (Green et al, 1980). Neither did we demonstrate any
relationship between lymphangiography and focal abnormalities
in the thyroid gland. Now that lymphangiography has been super-
seded by computerized tomography (CT) scan as a staging proce-
dure, any possible effect will be seen in a diminishing number of
patients.
In our study less than a quarter of the patients were treated with
doses of 2500 cGy or less, but our results are in accord with those
of Constine et al (1984) that patients in the low-dose group have a
lower incidence of subclinical hypothyroidism. This study did not
demonstrate a relationship between the dose of radiation and
development of thyroid nodules but the range of dose was small
(2250–4000 cGy) compared to the study of Crom et al (1997) in
which they demonstrated an increased relative risk of developing
thyroid nodules with increasing dose of thyroid irradiation.
RNI does not have a role in the regular follow-up of these
patients. The smallest nodule detected by RNI in this study was
1.3 cm in size, and only seven of 27 nodules of 0.5 cm or greater in
size, previously identified on ultrasound, were seen on RNI. When
the radionuclide scans were reviewed without knowledge of the
result of the ultrasound, the isolated nodule in the patient subse-
quently shown to have a thyroid carcinoma was not identified.
FNA biopsy has been shown by others (Gharib and Goeilner,
1993) to be a useful technique in the management of patients with
thyroid nodules. In our limited experience we did not find this to
be the case. In five of 11 patients the biopsy was non-contributory.
In our patients, however, nodules being aspirated seldom exceeded
1.0–1.5 cm, smaller than in those patients presenting with palpable
thyroid masses. Given that thyroid carcinoma may present
with multiple small foci, and that benign and malignant lesions
may coexist, the value of a negative biopsy in this situation is
questionable.
Ten patients had thyroid surgery, the majority of whom had
either total or subtotal thyroidectomy. It has been shown by
Fogelfeld et al (1989) that recurrence of thyroid nodules after
surgical removal in patients irradiated in childhood for benign
conditions is related to the amount of thyroid tissue remaining. In
view of these findings and the continuing risk of malignant change
in a previously irradiated thyroid gland, unilateral lobectomy in
a patient with multiple focal abnormalities of the thyroid on
Table 4 Association of raised TSH level and thyroid nodules on ultrasound with lymphangiography and dose of radiotherapy
Normal TSH Raised TSH
Lymphangiogram Yes 10 17 (62%)
No 7 12 (63%)
Radiotherapy ≤ 2500 cGy 5 6 (54%)
> 2500 cGy 12 23 (66%)
No focal abnormality Focal abnormality
Lymphangiogram Yes 5 22 (81%)
No 4 16 (80%)
Radiotherapy ≤ 2500 cGy 3 8 (72%)
> 2500 cGy 8 28 (78%)Post-radiation thyroid disease in childhood Hodgkin’s 813
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ultrasound is of doubtful benefit as the patient will need to be on
thyroxine and will also need to continue to have regular thyroid
ultrasound scans.
The three observed cases of thyroid cancer may be compared
with an expected number of about one in 400 (for ages 10–29
years) based on cancer registration rates for England and Wales (G
Draper, personal communication). This excess is almost certainly
exaggerated since the registration rates are based on clinically
diagnosed symptomatic cases, whereas the three cases in the
present study were discovered during a period of close surveil-
lance, using ultrasound, and at the time of diagnosis all patients
were symptom-free. However, even allowing for this, the observed
incidence of three cases in 47 patients is vastly in excess of the
expected incidence of one in 400.
Follow-up
There is no consensus of opinion on the best way to follow-up
patients whose treatment for malignant disease has included radio-
therapy to the neck. Clinical examination can be insensitive, whilst
thyroid ultrasound, because of its sensitivity, may result in the detec-
tion of nodules of uncertain clinical significance – the so-called inci-
dentalomas (Ezzat et al, 1994; Tan and Gharib, 1997). However, it is
known that patients treated with radiotherapy to the neck are at
increased risk of developing benign and malignant thyroid nodules.
The data on non-irradiated patients indicate that intra-thyroidal
papillary carcinoma has an excellant prognosis when diagnosed on
the basis of a clinically palpable abnormality (De Groot et al, 1990).
However, we cannot necessarily extrapolate those findings to the
post-irradiation situation. Thus, until we know the prognosis of
post-irradiation intra-thyroidal papillary carcinoma we recommend
that periodic ultrasound examination should be included in the
follow-up of patients treated with neck radiotherapy.
We suggest the following as a suitable protocol for the follow up
of all patients whose treatment for Hodgkin’s disease included
radiotherapy to the neck.
1. Clinical examination with careful palpation of the thyroid
gland.
2. Measurement of TSH and thyroxine levels every 6 months for
the first 5 years and then annually.
3. If TSH levels remain elevated for 1 year, institute treatment
with thyroxine in a dose sufficient to suppress the TSH level to
< 1 mu l–1.
4. For patients on thyroxine, because of previously elevated TSH
levels, and a normal thyroid ultrasound, consider stopping
thyroxine after 5 years and monitoring thyroid function tests to
determine whether continuing treatment with thyroxine is
necessary.
5. The first thyroid ultrasound should be done 3 years from the
end of radiotherapy and yearly thereafter.
6. Fine needle aspiration biopsy of the thyroid gland and/or
surgery should be considered for lesions of 1 cm or greater, or
for any lesion which increases markedly in size or changes in
character, especially in a patient with normal TSH levels.
CONCLUSIONS
Ultrasonography is the most sensitive method for detecting thyroid
abnormalities but cannot distinguish between benign and malignant
nodules (Garcia et al, 1992). It can, however, be used to document
change both in size and character of focal lesions. FNA biopsy, in
centres with the necessary expertise, or surgery should be consid-
ered for patients with both solitary and multiple focal abnormalities
of the thyroid gland when there are lesions measuring 1 cm or
greater, and in particular for patients whose nodules show a marked
increase in size or change in character on serial scanning.
Suppressive doses of thyroxine are indicated for patients with an
elevated TSH. The use of thyroxine should be considered, probably
within a trial set-up, for patients with normal TSH levels who
develop focal nodules to ascertain whether or not thyroxine results
in regression of nodules and prevents the development of new
nodules.
Long-term follow-up of patients treated by neck irradiation
during childhood is essential because of the long natural history of
the development of thyroid dysfunction.
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